Amitriptyline for Crohn's Disease

(AIMS-CD Trial)

This trial explores whether amitriptyline, a medication often used for treating irritable bowel syndrome (IBS), can reduce stomach pain and bloating in people whose Crohn's disease is in remission. The trial aims to determine if this treatment is safe and effective for those who still experience these symptoms despite having their inflammation under control. Participants will receive either amitriptyline or a placebo (an inactive pill) to compare the results. Those who may qualify have Crohn's disease in remission but still experience frequent stomach discomfort and changes in bowel habits. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial requires that your current Crohn's disease medications remain stable for at least 90 days before starting and during the study. However, you cannot participate if you are currently using tricyclic antidepressants, monoamine oxidase inhibitors, or other medications that interact with amitriptyline.

Research has shown that amitriptyline is usually well-tolerated for stomach and digestive issues. In studies on irritable bowel syndrome (IBS), few participants discontinued low-dose amitriptyline due to side effects. Specifically, about 20% of patients on amitriptyline stopped treatment, compared to 26% on a placebo, suggesting it is manageable for most people.

Amitriptyline is already used to treat IBS and has proven effective in reducing stomach pain and improving the quality of life for those with digestive problems. Its anti-inflammatory effects might also benefit individuals with Crohn's disease.

Most treatments for Crohn's disease, like biologics and immunosuppressants, work by dampening the immune system to reduce inflammation. But amitriptyline, typically used as an antidepressant, works differently, and researchers are curious about its potential to target nerve pathways and gut-brain interactions. This unique mechanism might address symptoms more holistically, offering relief beyond just inflammation control. Researchers are excited because it could provide a new option for patients who don't respond well to current treatments.

Studies have shown that amitriptyline can help with stomach issues like irritable bowel syndrome (IBS). Specifically, taking a low dose of amitriptyline greatly improved IBS symptoms compared to a placebo. It has also helped people with inflammatory bowel disease (IBD), with most patients experiencing some improvement. Research suggests that amitriptyline can enhance the quality of life for some people with Crohn's disease. While more studies are needed for inactive Crohn's disease, current evidence indicates that amitriptyline might help reduce belly pain and other ongoing symptoms. Participants in this trial will receive either amitriptyline or a placebo to evaluate its effectiveness specifically for Crohn's disease.¹²³⁴⁶